Home Cart 0 Sign in  

[ CAS No. 202189-78-4 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 202189-78-4
Chemical Structure| 202189-78-4
Structure of 202189-78-4 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 202189-78-4 ]

Related Doc. of [ 202189-78-4 ]

Alternatived Products of [ 202189-78-4 ]

Product Details of [ 202189-78-4 ]

CAS No. :202189-78-4 MDL No. :
Formula : C28H37N3O3 Boiling Point : -
Linear Structure Formula :- InChI Key :ACCMWZWAEFYUGZ-UHFFFAOYSA-N
M.W : 463.61 Pubchem ID :185460
Synonyms :
F-96221-BM1

Calculated chemistry of [ 202189-78-4 ]

Physicochemical Properties

Num. heavy atoms : 34
Num. arom. heavy atoms : 15
Fraction Csp3 : 0.5
Num. rotatable bonds : 10
Num. H-bond acceptors : 5.0
Num. H-bond donors : 1.0
Molar Refractivity : 140.53
TPSA : 67.59 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : Yes
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : Yes
CYP3A4 inhibitor : Yes
Log Kp (skin permeation) : -7.51 cm/s

Lipophilicity

Log Po/w (iLOGP) : 3.89
Log Po/w (XLOGP3) : 2.28
Log Po/w (WLOGP) : 4.48
Log Po/w (MLOGP) : 3.29
Log Po/w (SILICOS-IT) : 4.88
Consensus Log Po/w : 3.76

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -3.82
Solubility : 0.0706 mg/ml ; 0.000152 mol/l
Class : Soluble
Log S (Ali) : -3.34
Solubility : 0.214 mg/ml ; 0.000461 mol/l
Class : Soluble
Log S (SILICOS-IT) : -7.31
Solubility : 0.0000229 mg/ml ; 0.0000000494 mol/l
Class : Poorly soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 2.0
Synthetic accessibility : 4.15

Safety of [ 202189-78-4 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P280-P305+P351+P338 UN#:N/A
Hazard Statements:H302 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 202189-78-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 202189-78-4 ]

[ 202189-78-4 ] Synthesis Path-Downstream   1~8

  • 1
  • [ 202189-77-3 ]
  • [ 202189-78-4 ]
YieldReaction ConditionsOperation in experiment
93% With potassium hypochlorite; tetrabutylammonium hydrogensulfate In water monomer; ethyl acetate at 20℃; for 12h; 1-6 Example 2: 10g2-[1-(2-{4-[1-(4,4-dimethyl-4,5-dihydro-oxazol-2-yl)-1-methyl-ethyl]-phenyl} -ethyl)-piperidin-4-yl]1-(2-ethoxy-ethyl)-1H-benzimidazole was dissolved in 200 ml of ethyl acetate.0.6 g of tetrabutylammonium hydrogen sulfate, 130 ml of potassium hypochlorite solution was added, and the mixture was stirred at room temperature for 12 hours.Acidified with hydrochloric acid to pH < 2, extracted with ethyl acetate, concentrated, added with methanol, aqueous sodium hydroxide,Stir at room temperature for 24 h, acidify with hydrochloric acid to pH=7, extract with dichloromethane and concentrate.A white solid was obtained in a yield of 93%.
93.5% With succinic acid for 36h; Reflux; 1-9 Example 5 5 g of 2-[1-(2-{4-[1-(4,4-dimethyl-4,5-dihydro-oxazol-2-yl)-1-methyl-ethyl]phenyl}-ethyl)-piperidin-4-yl]-1-(2-ethoxy-ethyl)-1H-benzimidazole was added to a clean three-necked flask, and 75 ml of a 3N succinic acid solution was added. was heated at reflux for 36 hours, washed with 10% aqueous sodium hydroxide solution was adjusted to pH = 7, extracted with dichloromethane, spin solvent to give a white solid, 93.5% yield
87% Stage #1: 2-[1-(2-{4-[1-(4,4-dimethyl-4,5-dihydro-oxazol-2-yl)-1-methylethyl]phenyl}ethyl)piperidin-4-yl]1-(2-ethoxyethyl)-1H-benzimidazole With hydrogenchloride; water monomer Reflux; Stage #2: With sodium hydroxide In water monomer 19 Example 19: Preparation of2-[4-(2-{4-[1 -(2-ethoxy-ethyl)-1 H-benzoimidazol-2-yl]-piperidin-1 -yl}-ethyl)- phenyl]-2-methyl-propionic acid; In a reaction vessel,2-[1-(2-{4-[1-(4,4-dimethyl-4,5-dihydro-oxazol-2-yl)-1-methyl-ethyl]-phenyl}-ethyl )-piperidin-4-yl]-1-(2-ethoxy-ethyl)-1 H-benzoimidazole(4.4g) prepared in the Example 18 and hydrochloric acid aqueous solution(50mL) were introduced, and the mixture was stirred with reflux. After the reaction was completed, sodium hydroxide solution was added to control the pH to 7. Ethylacetate(50mL) was added to separate a layer, and the organic layer was condensed under reduced pressure. And, butanol(9ml_) was added and dissolved by heating. And then, it was cooled to precipitate crystals, and the crystals were filtered under reduced pressure to obtain2-[4-(2-{4-[1 -(2-ethoxy-ethyl)-1 H-benzoimidazol-2-yl]-piperidin-1 -yl}-ethyl)-pheny l]-2-methyl-propionic acid (3.43g, yield 87%, HPLC purity 99% or more).1H-NMR, 400MHz, CDCI3, ppm : δ1.08(t, 3H), 1.59(s, 6H)1 2.15-2.30(m. 4H), 2.64-2.79(m, 6H), 3.25(s, 1 H), 3.67(q, 2H), 3.47(m, 2H), 3.71 (t, 2H), 4.32(t, 2H), 6.79(d, 2H), 7.26(m, 2H), 7.29-7.32(m, 3H), 7.76(t, 1 H)
87% With hydrogenchloride; water monomer Reflux; 19 Example 19 Preparation of 2-[4-(2-{4-[1-(2-ethoxy-ethyl)-1H-benzoimidazol-2-yl]-piperidin-1-yl}-ethyl)-phenyl]-2-methyl-propionic acid In a reaction vessel, 2-[1-(2-{4-[1-(4,4-dimethyl-4,5-dihydro-oxazol-2-yl)-1-methyl-ethyl]-phenyl}-ethyl)-piperidin-4-yl]-1-(2-ethoxy-ethyl)-1H-benzoimidazole (4.4 g) prepared in the Example 18 and hydrochloric acid aqueous solution (50 mL) were introduced, and the mixture was stirred with reflux. After the reaction was completed, sodium hydroxide solution was added to control the pH to 7. Ethylacetate (50 mL) was added to separate a layer, and the organic layer was condensed under reduced pressure. And, butanol (9 mL) was added and dissolved by heating. And then, it was cooled to precipitate crystals, and the crystals were filtered under reduced pressure to obtain 2-[4-(2-{4-[1-(2-ethoxy-ethyl)-1H-benzoimidazol-2-yl]-piperidin-1-yl}-ethyl)-phenyl]-2-methyl-propionic acid (3.43 g, yield 87%, HPLC purity 99% or more). 1H-NMR, 400 MHz, CDCl3, ppm: 61.08 (t, 3H), 1.59 (s, 6H), 2.15-2.30 (m. 4H), 2.64-2.79 (m, 6H), 3.25 (s, 1H), 3.67 (q, 2H), 3.47 (m, 2H), 3.71 (t, 2H), 4.32 (t, 2H), 6.79 (d, 2H), 7.26 (m, 2H), 7.29-7.32 (m, 3H), 7.76 (t, 1H)
85% Stage #1: 2-[1-(2-{4-[1-(4,4-dimethyl-4,5-dihydro-oxazol-2-yl)-1-methylethyl]phenyl}ethyl)piperidin-4-yl]1-(2-ethoxyethyl)-1H-benzimidazole With acetic acid In water monomer for 3h; Reflux; Stage #2: With water monomer; sodium hydroxide Reflux; 1; 2; 3; 4; 5; 6; 7 Preparation of bislastine (1) 100g of compound IV was added to glacial acetic acid 20g, water was added to 100ml, and heated under reflux for 3 hours to obtain a light yellow aqueous solution, 200 ml of water was added, 150 g of sodium hydroxide was added, and the mixture was stirred under reflux for 2-3 hours, and then cooled to room temperature, dichloromethane 100 ml. Stirring extraction,The methylene chloride was recovered to obtain a white solid of bilastine sodium salt, 200 ml of water was added, and 5N hydrochloric acid was used to adjust the pH to 7-8.A large amount of white crystalline form of bilastine was precipitated, and after stirring for 3 hours, it was filtered to obtain 75 g of a white solid, a yield of 85%, and a purity of 99.4%.
With hydrogenchloride In water monomer Reflux; 3; 13; 15 Example 3: Preparation of 2-(4-(2-(4-(l-(2-ethoxyethyl)-lH- benzo[d]imidazol-2-yl)piperidin-l-yl)ethyl)phenyl)-2-methylpropanoic acid p- xylene solvate (p-xylene solvate of bilastine) (2-(2-(4-(2-(4-(l-(2-ethoxyethyl)-lH-benzo[d]imidazol-2-yl)piperidin-l-yl)ethyl) phenyl)propan-2-y l)-4,4-dimethy 1-4, 5 -dihy drooxazole(37gm, 0.071 mmol) was mixed with 50% hydrochloric acid and the reaction mass was heated to reflux temperature for about 5h to about 6h and then reaction mass cooled to about 25°C to about 30°C. 20% methanol in dichloromethane was then added to the reaction mass and 20% aqueous sodium hydroxide solution was added to the reaction mass to adjust the pH of the reaction mass to 7. The aqueous and organic layers were separated. The organic layer was washed with saturated sodium chloride solution and dried over sodium sulphate and solvent was removed under reduced pressure to obtained semisolid residue. The p-xylene and methanol solvent mixture (volume ratio p-xylene: methanol is 85: 15 V/V) was added to the obtained residue and the reaction mass was heated in the temperature range of 65°C to 70°C for about 30min. The reaction mass was then cooled in the temperature range of 25°C to 30°C and the reaction was further cooled in the temperature range of l5°C to 20 °C. Then the reaction mass was stirred followed by filtration and the product was dried to obtained title compound. The obtained title compound was characterized by Hl NMR (400 MHz, DMSO-d6): l .0l(t,3H), l .46(s,6H), l .9l(m,4H), 2. l3(m,2H), 2.25(s,4H), 2.54(t,2H), 2.75(t,2H), 3.07(m,3H), 3.34(q,2H), 3.65(t,2H), 4.40(t,2H), 7.05(s,2H), 7. l4-7.28(m,6H), 7.51-7.57 (m,2H).
With hydrogenchloride; water monomer

  • 2
  • [ 1181267-38-8 ]
  • [ 202189-78-4 ]
YieldReaction ConditionsOperation in experiment
96% With water; sodium hydroxide In ethanol for 16h; Reflux; 8 Example 8: preparation of 2-(4-{2-[4-(1-(2-ethoxyethyl)-1H-benzimidazol-2-yl)piperidin-1-yl]ethyl} phenyl)-2-methylpropionic acid In a reaction vessel, 2-(4-{2-[4-(1-(2-ethoxyethyl)-1H-benzimidazol-2-yl)piperidin-1-yl]ethyl}phenyl)- 2-methylpropionic acid methyl ester obtained in Example 1 was added.Methylimidazol-2-yl)-piperidin-1-yl]-ethyl}phenyl)-2-methyl-propionic acid methyl ester (2.0 g), sodium hydroxide 0.5 g, water 1 mL andEthanol 20 mL, heated to reflux for 16 hours, cooled to room temperature, concentrated under reduced pressure, added 20 mL of water, and adjusted pH with dilute hydrochloric acid solutionNeutral, stirred for one hour, filtered to give 2-(4-{2-[4-(1-(2-ethoxyethyl)-1H-benzimidazol-2-yl)piperidin-1-yl]ethyl} phenyl)-2-methylpropionic acid(1.8 g, 96% yield).
96% With sodium hydroxide In ethanol; water for 7h; Reflux; 21 Example 21: 2-(4-{2-[4-(1-(2-ethoxyethyl)-1H-benzimidazol-2-yl)-piperidin-1-yl]-Ethyl}phenyl)-2-methyl-propionic acidPreparation In a reaction vessel,Added Example 152-(4-{2-[4-(1-(2-ethoxyethyl)-1H-benzimidazol-2-yl)-piperidin-1-yl]-ethyl}phenyl)- 2-Methyl-propionic acid methyl ester (2.0 g),0.5 g of sodium hydroxide, 1 mL of water, and 20 mL of ethanol were heated to reflux for 7 hours and cooled to room temperature.Concentrate under reduced pressure, add 20 mL of water, adjust pH to neutral with dilute hydrochloric acid solution, and stir for one hour.Filtration to give 2-(4-{2-[4-(1-(2-ethoxyethyl)-1H-benzimidazol-2-yl)-piperidin-1-yl]-ethyl}Phenyl)-2-methyl-propionic acid (1.8 g, yield 96%).
96% With methanol; sodium hydroxide for 5h; Reflux; 14 Example 14 Preparation of Bilastine Compound II (10g, 20.9mmol) was added to methanol (80mL), after dissolution, saturated sodium hydroxide solution (2.5g, 62.8mmol, 50%,) was added, heated to reflux for 5h, concentrated under reduced pressure to remove methanol, and the residue Dilute hydrochloric acid was added to adjust the pH to 4~5. After cooling, a solid was precipitated. The filter cake was washed with ice water (50 mL) and cold ethanol (50 mL). The methanol was recrystallized to obtain a pale yellow solid I (9.3 g, 96%).
92.1% With lithium hydroxide In methanol; water at 20℃; for 6h; 6 Preparation of bilastine To the reaction flask was added 500 mL of water, 500 mL of methanol, 11.3 g of lithium hydroxide and 43.2 g of the compound prepared in Example 4, and the mixture was stirred at room temperature for 6 hours. After completion of the reaction, the mixture was adjusted to pH 7 with 6N aqueous hydrochloric acid to precipitate a white solid Filtered and dried at 50 ° C under reduced pressure to give 38.6 g of white powder than lustin in a yield of 92.1%.
91.3% With methanol; sodium hydroxide at 0 - 20℃; for 3h; 3 Example 3: 4- [2- [1- (2-ethoxyethyl) benzimidazolyl] piperidinyl] ethyl-phenyl tert-butyric acid methyl ester (477g) was dissolved in methanol (3L) and cooled to 0 , 4N sodium hydroxide (500mL) was added dropwise, stirred at room temperature for 3h, concentrated to remove methanol, 36% hydrochloric acid (200mL) was added dropwise, solid precipitated, filtered, the filter cake was slurried with ethanol (800mL) for 1 hour, filtered,Bilastine (423 g) was obtained, yield: 91.3%, purity 99.5%.
90% Stage #1: methyl 2-(4-(2-(4-(1-(2-ethoxyethyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)ethyl)phenyl)-2-methylpropanoate With sodium hydroxide In ethanol at 50 - 55℃; for 3h; Stage #2: With acetic acid In ethanol; water 16 Example 16 Preparation of 2-[4-(2-{4-[1-(2-ethoxy-ethyl)-1H-benzoimidazol-2-yl]-piperidin-1-yl}-ethyl)-phenyl]-2-methyl-propionic acid In a reaction vessel, 2-[4-(2-{4-[1-(2-ethoxy-ethyl)-1H-benzoimidazol-2-yl]-piperidin-1-yl}-ethyl)-phenyl]-2-methyl-propionic acid methylester (2.3 g) prepared in the Example 14, sodium hydroxide (0.6 g) and ethylalcohol (13 mL) were introduced, and the mixture was reacted at 50-55° C. for 3 hours. Distilled water (20 mL) was added thereto, and acetic acid was added to control the pH to 7. Ethylacetate (50 mL) was added thereto, and the mixture was stirred to separate a layer. The separated organic layer was condensed under reduced pressure. And, butanol (9 mL) was added thereto, and dissolved by'heating. And then, it was cooled to precipitate crystals, and the crystals were filtered under reduced pressure to obtain 2-[4-(2-{4-[1-(2-ethoxy-ethyl)-1H-benzoimidazol-2-yl]-piperidin-1-yl}ethyl)-phenyl]-2-methyl-propionic acid (2.0 g, yield 90%, HPLC purity 99% or more). 1H-NMR, 400 MHz, CDCl3, ppm: 61.08 (t, 3H), 1.59 (s, 6H), 2.15-2.30 (m. 4H), 2.64-2.79 (m, 6H), 3.25 (s, 1H), 3.67 (q, 2H), 3.47 (m, 2H), 3.71 (t, 2H), 4.32 (t, 2H), 6.79 (d, 2H), 7.26 (m, 2H), 7.29-7.32 (m, 3H), 7.76 (t, 1H)
89.3% With water; sodium hydroxide In ethanol for 1h; Reflux; 9-11 Example 10 Preparation of Bilastine Into a 250mL reaction flask, sequentially add 140mL of ethanol, 14.33g of the compound V obtained in Example 10,7mL water and 3.6g sodium hydroxide. Heat to reflux for 1h,TLC detected that the reaction of Compound V was complete, the ethanol was distilled off under reduced pressure at 40°C, and 70 mL of water was added.Stir to dissolve, wash three times with 30 mL of ethyl acetate, adjust pH to 6.5 with 1.2 mol/L hydrochloric acid, stir for 1 h, and filter.Add 150mL of isopropanol, stir and heat to reflux for 1h, drop to room temperature, stir for 1h, filter, and vacuum dry at 50,12.42 g derbystatin was obtained, the yield was 89.3%, the purity by HPLC detection was 99.9%, and the maximum single impurity was 0.06%.
82.2% Stage #1: methyl 2-(4-(2-(4-(1-(2-ethoxyethyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)ethyl)phenyl)-2-methylpropanoate With water; sodium hydroxide In ethanol for 3h; Reflux; Stage #2: With hydrogenchloride In water at 20℃; 1.2; 1.3; 2.2; 2.3; 3.2; 3.3 (2) Preparation of crude bilastineThe above-derived bilastine methyl ester (23.88 g, 0.05 mol) was added to ethanol (75 ml), followed by the addition of sodium hydroxide(3g, 0.075mol) of a 30% aqueous solution,After refluxing for 3 hours, the reaction solution was cooled to room temperature and concentrated hydrochloric acid was added.The solution has a pH between 5 and 6 and a pale yellow solid precipitates.The filter cake was washed twice with ice water and iced ethanol.The filter cake was dried to give a crude product (20.50 g, 88.5%).(3) Preparation of bilastineThe crudebilastine (23.2 g, 0.05 mol) obtained in the previous step was placed in n-butanol (500 ml), and then activated carbon (0.5 g) was added to reflux system for 5 hours.After hot filtration, the filtrate was naturally cooled to room temperature and filtered to dryness to give the crystalline form of bilastine (19.07 g, 82.2%).
64% Stage #1: methyl 2-(4-(2-(4-(1-(2-ethoxyethyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)ethyl)phenyl)-2-methylpropanoate With water; lithium hydroxide In tetrahydrofuran; methanol at 70℃; for 16h; Stage #2: With hydrogenchloride In tetrahydrofuran; methanol; water
Multi-step reaction with 2 steps 1: hydrogenchloride / diethyl ether / 0 - 5 °C 2: water; potassium hydroxide / methanol / 16 h / 100 °C / Inert atmosphere
7 g With sodium hydroxide In ethanol at 65 - 70℃; for 4h; 19; 20 Example-19: Preparation of 2-[4-(2-{4-[l-(2-ethoxyethyl)-lH-benzimidazoI-2-yl]-l- piperidinyl}ethyl)phenyl]-2-methylpropanoic acid (Formula-1) Example-19: Preparation of 2-[4-(2-{4-[l-(2-ethoxyethyl)-lH-benzimidazoI-2-yl]-l- piperidinyl}ethyl)phenyl]-2-methylpropanoic acid (Formula-1) A mixture of methyl 2-(4-(2-(4-(l-(2-eth0xyethyl)-lH-benzo[d]imidazol-2-yl) piperidin-l-yl)ethyl)phenyl)-2-methylpropanoate compound of formula- 13 (3 gm), sodium hydroxide (0.5 gm) and ethanol (21 ml) was heated to 65-70°C and stirred for 4 hrs at the same temperature. Water and dichloromethane were added to the reaction mixture and stirred for 15 min at the same temperature. Both the organic and aqueous layers were separated and the aqueous layer was neutralized using acetic acid. Extracted the aqueous layer with dichloromethane. Both the organic and aqueous layers were separated and the organic layer was washed with sodium chloride solution. Distilled off the solvent completely from the organic layer under reduced pressure to get the title compound. Yield: 1.3 gm. Example-20: Purification of 2-[4-(2-{4-[l-(2-ethoxyethyl)-lH-benzimidazoI-2-yl]-l- piperidinyl}ethyl)phenyI]-2-methylpropanoic acid (Formula-1) A mixture of 2-[4-(2-{4-[l-(2-ethoxyemyl)-lH-berizimidazol-2-yl]-l-piperidinyl} ethyl)phenyl]-2-methylpropanoic acid compound of formula-1 (8 gm) and n-butanol (75 ml) was heated to 110-115°C and stirred for 10 min at the same temperature. Carbon (0.8 gm) was added to the reaction mixture and stirred for 30 min at the same temperature. Filtered the reaction mixture through hyflow bed and washed the hyflow bed with n-butanol. Cooled the reaction mixture to 5-10°C and stirred for 30 min at the same temperature. Filtered the solid, washed with n-butanol and dried the material to get pure title compound. Yield: 7.0 gm; Purity by HPLC: 99.6%.
With lithium hydroxide In tetrahydrofuran
With hydrogenchloride In water
8.2 g With water; sodium hydroxide In ethanol at 25 - 40℃; 9-11 Example 9: Preparation of 2-(4-(2-(4-(1-(2-ethoxyethyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)ethyl)phenyl)-2-methylpropanoic acid (I) 15 g of compound (IV) was charged to 45 ml of ethanol at 25-30 °C. 3.8 g of sodium hydroxide dissolved in 45 ml of water was added to the reaction mixture. The reaction mixture was maintained at 35-40 °C. After completion of the reaction 45 ml of ethanol was added. The pH of the aqueous layer was adjusted to 6.5 to 7.5 using hydrochloric acid solution and then 100 ml of ethyl acetate was charged and stirred for Ihr at 25-30 °C. The solid was filtered and washed with 30 ml of ethyl acetate and dried at below 50 °C to obtain 2-(4-(2-(4-(1-(2-ethoxyethyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)ethyl)phenyl)-2-methylpropanoic acid (I). Yield: 8.2 g. Example 10: Purification of Bilastine (I) 10 g of Bilastine (I) was added to 50 ml of methanol and heated to 50-60 °C, stirred for 10 min. To the reaction mixture 50ml of acetone was added and stirred at 50-60 °C for 15 minutes. The reaction mass was cooled to 20-25 °C and stirred for 30 minutes. After completion of the reaction, the reaction mass was filtered and washed with 20 ml of methanol. To the filtrate, 30 ml of methanol was added and heated to 50-60 °C and stirred for 30 minutes. 1.0 g of activated carbon was added to the reaction mass and then stirred for 10 minutes. Then the reaction mass was filtered and washed with 10 ml of hot methanol. The filtrate was cooled to 20-22 °C and stirred for 40 minutes at 20-22 °C. The solid was filtered and washed with 10ml of cold methanol and dried at below 60-70 °C to obtain pure Bilastine (I). Yield: 7.0 g; Purity: 99.9%. Example 11: Purification of Bilastine (I) A mixture of 10 g of Bilastine(I) and 75 ml of isopropyl alcohol was heated to SO- 85 °C and stirred for 30 min at 80-85 °C. The reaction mixture was cooled to 5-10 °C and stirred for 30 min. The obtained solid was filtered, washed with 25 mL isopropyl alcohol, and dried the material to get pure Bilastine (I). Yield: 7.0 g; Purity: 99.89%.
8.2 g With water; sodium hydroxide In ethanol at 25 - 40℃; 9-11 Example 9: Preparation of 2-(4-(2-(4-(1-(2-ethoxyethyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)ethyl)phenyl)-2-methylpropanoic acid (I) 15 g of compound (IV) was charged to 45 ml of ethanol at 25-30 °C. 3.8 g of sodium hydroxide dissolved in 45 ml of water was added to the reaction mixture. The reaction mixture was maintained at 35-40 °C. After completion of the reaction 45 ml of ethanol was added. The pH of the aqueous layer was adjusted to 6.5 to 7.5 using hydrochloric acid solution and then 100 ml of ethyl acetate was charged and stirred for Ihr at 25-30 °C. The solid was filtered and washed with 30 ml of ethyl acetate and dried at below 50 °C to obtain 2-(4-(2-(4-(1-(2-ethoxyethyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)ethyl)phenyl)-2-methylpropanoic acid (I). Yield: 8.2 g. Example 10: Purification of Bilastine (I) 10 g of Bilastine (I) was added to 50 ml of methanol and heated to 50-60 °C, stirred for 10 min. To the reaction mixture 50ml of acetone was added and stirred at 50-60 °C for 15 minutes. The reaction mass was cooled to 20-25 °C and stirred for 30 minutes. After completion of the reaction, the reaction mass was filtered and washed with 20 ml of methanol. To the filtrate, 30 ml of methanol was added and heated to 50-60 °C and stirred for 30 minutes. 1.0 g of activated carbon was added to the reaction mass and then stirred for 10 minutes. Then the reaction mass was filtered and washed with 10 ml of hot methanol. The filtrate was cooled to 20-22 °C and stirred for 40 minutes at 20-22 °C. The solid was filtered and washed with 10ml of cold methanol and dried at below 60-70 °C to obtain pure Bilastine (I). Yield: 7.0 g; Purity: 99.9%. Example 11: Purification of Bilastine (I) A mixture of 10 g of Bilastine(I) and 75 ml of isopropyl alcohol was heated to SO- 85 °C and stirred for 30 min at 80-85 °C. The reaction mixture was cooled to 5-10 °C and stirred for 30 min. The obtained solid was filtered, washed with 25 mL isopropyl alcohol, and dried the material to get pure Bilastine (I). Yield: 7.0 g; Purity: 99.89%.

Reference: [1]Current Patent Assignee: LUOXIN PHARMACEUTICALS GROUP STOCK CO LTD - CN107365298, 2017, A Location in patent: Paragraph 0079-0080
[2]Current Patent Assignee: LUOXIN PHARMACEUTICALS GROUP STOCK CO LTD - CN107365297, 2017, A Location in patent: Paragraph 0127; 0128
[3]Current Patent Assignee: CHANGZHOU UNIVERSITY - CN113292534, 2021, A Location in patent: Paragraph 0101-0102
[4]Current Patent Assignee: BEIJING COLLAB PHARMA CO LTD - CN104177331, 2016, B Location in patent: Paragraph 0089-0091
[5]Current Patent Assignee: SHANGHAI TIANCI ZHONGSHANG PHARMACEUTICAL - CN110950837, 2020, A Location in patent: Paragraph 0079; 0080
[6]Current Patent Assignee: YUHAN CORPORATION - US2011/9636, 2011, A1 Location in patent: Page/Page column 7
[7]Current Patent Assignee: LUOXIN PHARMACEUTICALS GROUP STOCK CO LTD - CN111039922, 2020, A Location in patent: Paragraph 0055-0060
[8]Current Patent Assignee: BEIJING THTD PHARMACEUTICAL TECH - CN109081827, 2018, A Location in patent: Paragraph 0078; 0081-0084; 0085; 0088-0091; 0092; 0095-0098
[9]Location in patent: experimental part Collier, Steven J.; Wu, Xiang; Poh, Zhiying; Rajkumar, Gurubatham Abraham; Yet, Larry [Synthetic Communications, 2011, vol. 41, # 9, p. 1394 - 1402]
[10]Current Patent Assignee: ADVENT INTERNATIONAL CORPORATION - WO2014/26657, 2014, A2
[11]Current Patent Assignee: MSN LABORATORIES PRIVATE LIMITED - WO2014/188453, 2014, A2 Location in patent: Page/Page column 30
[12]Kommera, Rajashekar; Yerrabelly, Jayaprakash Rao; Kasireddy, Venkateshwarreddy; Ghojala, Venkat Reddy; Singavarapu, Adilakshmi; Rebelli, Pradeep [Letters in Organic Chemistry, 2018, vol. 15, # 10, p. 815 - 821]
[13]Current Patent Assignee: OCIMUM LABS PRIVATE - WO2022/214921, 2022, A1 Location in patent: Page/Page column 3
[14]Current Patent Assignee: BIOPHORE INDIA PHARMACEUTICALS PVT LTD - WO2023/37184, 2023, A2 Location in patent: Page/Page column 10-11
[15]Current Patent Assignee: BIOPHORE INDIA PHARMACEUTICALS PVT LTD - WO2023/37184, 2023, A2 Location in patent: Page/Page column 10-11
  • 3
  • [ 1567835-77-1 ]
  • [ 202189-78-4 ]
YieldReaction ConditionsOperation in experiment
58% With water; potassium hydroxide In methanol at 100℃; for 16h; Inert atmosphere; 12 Example 12: Preparation of 2-(4-(2-(4-(l -(2-ethoxyethyl)-l H-benzo[d]imidazol-2- yl)piperidin- 1 -yl)ethyl)pheny l)-2-methylpropanoic acid (bilastine) 9 bilastine methyl ester hydrochloride (8.69 g, 16.92 mmol) was dissolved in methanol (86 ml) and then a solution of potassium hydroxide (4.75 g, 84.62 mmol, 5.0 eq) in water (86 ml) was added under stirring and the reaction mixture was heated at 100°C under nitrogen for 16 h. Then, the bath temperature was increased to 120°C and methanol was removed by distillation at patm (ca. 1 18 ml of the distillate was removed, up to the boiling point of 98°C). After cooling to RT the mixture was washed with MTBE (3 x 50 ml) and the aqueous phase was then acidified to pH 7 by addition of 1 M HC1 (ca. 40 ml) under stirring; ethyl acetate (100 ml) was added to the precipitate of the product in the aqueous phase and the mixture was intensively stirred for 20 min. Then, the precipitate was filtered off, washed with water (10 ml) and ethyl acetate (10 ml) and dried in vacuum (55°C/18 kPa, 2h) -4.58 g of a white crystalline substance was obtained (58%, melt, point 199.9-203.8°C, lit. 58%, 199-201 °C, HPLC 99.61 %). and 13C NMR spectra in dDMSO are in conformity with the literature (EP 0 818 454 Al). The aqueous phase was additionally washed with ethyl acetate (2 x 100 ml) and the combined organic extracts were dried over Na2S0 and evaporated after filtration of the drying agent; 0.55 g of the product was obtained (HPLC 91.1 %). The crude product I was purified by crystallization from isopropanol (0.510 g sample from 40 ml of i-PrOH), 0.466 g (91%) of a crystalline substance with the HPLC purity of 99.80%) was obtained, polymorph 1 in accordance with IR (EP 1 505 066), Form 1 : XRPD ([°2Th.](rel. int%)): 3.64 (4.4), 10.57 (23.3), 1 1.27 (78.1), 12.47 (38.8), 14.08 (26.9), 15.07 (38.4), 15.50 (16.5), 16.27 (43.6), 17.16 (100.0), 18.89 (71.8), 19.73 (74.0), 21.13 (33.9), 22.17 (18.1), 22.71 (26.9), 23.34 (10.3), 24.88 ( 18.6), 25.82 (9.2), 26.58 ( 1 1.5), 28.43 (9.7), 29.16 (8.8), 30.92 (4.6), 34.38 (9.5), 37.01 (5.4). Crystallization of the API from n-pentanol (0.375 g from 3.75 ml) provided the yield of 0.125 g (33%), HPLC purity improved from 95.60% to 97.90%, form 2 in accordance with IR was provided (EP 1 505 066). Form 2: XRPD ([°2Th.](rel. int %)): 6.53 (100.0), 9.43 (30.8), 1 1.04 (22.8), 13.39 (6.2), 15.24 (32.2), 15.86 (86.1), 18.07 (29.9), 18.39 (36.2), 18.94 (8.3), 20.19 (16.0), 20.66 (19.0), 21.70 (17.1), 22.17 (15.6), 23.70 (5.7), 26.59 (4.9), 28.03 (3.6), 28.33 (3.6), 29.70 (4.3).
  • 4
  • [ 202189-78-4 ]
  • [ 103-90-2 ]
  • [ 1979965-41-7 ]
YieldReaction ConditionsOperation in experiment
85.3% Stage #1: Bilastine With thionyl chloride for 3h; Reflux; Stage #2: 4-acetaminophenol With pyridine In acetone at 20℃; for 5h; Cooling with ice; Compound (preparation) of The (1g, 2mmol) Compound () was dissolved in 15mL of thionyl chloride and refluxed for 3h.It was removed by distillation under reduced pressure thionyl chloride, ice-water cooling, were successively added 10mL of acetone, pyridine and 5mL (0.33g, 2mmol) of the compound (), room temperature for 5h.The filtrate was concentrated to dryness under reduced pressure, 10 mL of saturated brine was added and the mixture was filtered.The filter cake was washed with distilled water, dried and recrystallized from acetone to give 1.1 g of white crystals in a yield of 85.3%.
  • 5
  • [ 2159846-16-7 ]
  • [ 110963-63-8 ]
  • [ 202189-78-4 ]
YieldReaction ConditionsOperation in experiment
88% Stage #1: 2-methyl-2-(4-(2-oxoethyl)phenyl)propionic acid; 1-(2-ethoxyethyl)-2-(piperidin-4-yl)-1H-benzo[d]imidazole In tetrahydrofuran at 20℃; for 5h; Stage #2: With sodium tetrahydroborate In tetrahydrofuran at 20℃; for 16h; 20 Example 20: 2-(4-{2-[4-(1-(2-ethoxyethyl)-1H-benzimidazol-2-yl)-piperidin-1-yl]-Ethyl}phenyl)-2-methyl-propionic acidPreparation In a reaction vessel, 2-methyl-2-(4-(2-oxoethyl)phenyl)propionic acid prepared in Example 7 was added(1.0g),1-(2-Ethoxyethyl)-2-piperidin-4-yl-1H-benzimidazole (1.3 g), tetrahydrofuran (15 mL),The reaction was stirred at room temperature for 5 hours, sodium borohydride (4.2 g) was added, and the reaction was carried out at room temperature for 16 hours.The mixture was filtered, and the filtrate was concentrated under reduced pressure. 10 mL of dichloromethane and 5 mL of saturated sodium bicarbonate solution were added and stirred for 1 hour.Separate the organic phase, dry with 1 g of anhydrous sodium sulfate for 2 hours, and filter.The resulting filtrate was concentrated under reduced pressure to give 2-(4-{2-[4-(1-(2-ethoxyethyl)-1H-benzimidazol-2-yl)-Piperidin-1-yl]-ethyl}phenyl)-2-methyl-propionic acid (2.0 g, yield 88%).
  • 6
  • [ 628-34-2 ]
  • [ 1181267-37-7 ]
  • [ 202189-78-4 ]
YieldReaction ConditionsOperation in experiment
91.5% Stage #1: 2-chloroethyl ethyl ether; 2-(4-{2-[4-(1H-benzoimidazol-2-yl)-piperidin-1-yl]-ethyl}phenyl)-2-methyl-propionic acid methyl ester With potassium hydroxide In N,N-dimethyl acetamide at 60℃; for 3h; Stage #2: With methanol; sodium hydroxide for 3h; Reflux; 8-10; 5 Example 9 Preparation of Bilastine In a 250 mL reaction flask, add 20.28 g of compound V obtained in Example 4, 5.43 g of compound VI, 100 mL of N, N-N-dimethylacetamide, add 8.42 g of potassium hydroxide, and raise the temperature to 60 ° C for reaction. After 3 h, the reaction was monitored by TLC There is almost no raw material left, concentrate under reduced pressure, cool to 0 10 , add 100mL of water, add ethyl acetate 40mL * 3 and extract three times, combine organic phases, wash twice with saturated sodium chloride solution 50mL * 2, add anhydrous sulfuric acid Sodium 5.0g was dried for 30min, concentrated under reduced pressure, 60mL of methanol was added, 30mL of saturated sodium hydroxide solution was added, the reaction was refluxed for 3h, slowly added 4mol / L hydrochloric acid to adjust to pH 7.0, a light yellow solid was precipitated, suction filtered, the filter cake was iced Wash with 40 mL of water, recrystallize with methanol after drying, and vacuum dry at 40 ° C for 4 h to obtain 21.20 g of bilastine, yield 91.5%, purity 99.9%, maximum single impurity 0.06%
  • 7
  • [ 628-34-2 ]
  • [ 2099128-83-1 ]
  • [ 202189-78-4 ]
YieldReaction ConditionsOperation in experiment
84.8% Stage #1: 2-(4-{2-[4-(1H-benzimidazol-2-yl)piperidin-1-yl]ethyl}phenyl)-2-methylpropionic acid With sodium hydride In N,N-dimethyl-formamide for 0.5h; Stage #2: 2-chloroethyl ethyl ether In N,N-dimethyl-formamide at 50℃; for 1h; 1.3; 3.3 Step 3: Preparation of bilastine 20.1g 2-(4-{2-[4-(1H-benzimidazol-2-yl)piperidin-1-yl]ethyl}phenyl)-2-methylpropionic acid. Put 40ml of DMF into the reaction flask, and slowly add 4.5g of 60% sodium hydride, react for half an hour after the addition is complete, add 5.8g of 2-chloroethyl ether, and heat to 50°C for 1 hour, then slowly add to the reaction flask after the reaction 80ml of deionized water was added, and the pH value was adjusted to 7 with glacial acetic acid, filtered, and the filter cake was washed with water and then air-dried at 70°C for 3 hours to obtain 20.1 g of white solid with a yield of 84.8%.
  • 8
  • [ 2782052-73-5 ]
  • [ 202189-78-4 ]
YieldReaction ConditionsOperation in experiment
96.8% With 10% Pd/C; cyclohexene In toluene at 105 - 110℃; 21-29 Example 21 At room temperature, intermediate I-2 (23.08 g, 0.05 mol), cyclohexene (7.39g, 0.09mol), 10% palladium on carbon (2.31g) was added to toluene (250ml), The temperature is controlled at 105 to 110 °C for the reaction, After the reaction is completed, The reaction solution was cooled to room temperature, filter, The filtrate was washed with purified water (80ml×2), Washed with saturated brine (80ml×2), dried over anhydrous sodium sulfate, filter, The filtrate is concentrated to dryness under reduced pressure and is the target product bilastine I, Yield 96.8%, Purity 99.90%.
Same Skeleton Products
Historical Records